Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
−Removed: Holders of Common Stock
−Removed: As of March 15, 2020, there were 37 holders of record of our common stock.
+Added: Our common stock is listed on the Nasdaq Global Select Market under the trading symbol “CRTX”.
+Added: Our common stock has been traded on The Nasdaq Global Select Market since May 9, 2019 under the ticker symbol “CRTX”.
+Added: As of February 15, 2021, there were 17 holders of record of our common stock.
The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.
+Added: Stock Price Performance Graph
+Added: The following stock performance graph compares our total stock return with the total return for (i) the Nasdaq Composite Index and the (ii) the Nasdaq Biotechnology Index for the period from May 9, 2019 through December 31, 2020.
+Added: The figures represented below assume an investment of $100 in our common stock at the closing price of $32.89 on the date of our IPO, May 9, 2019 and in the Nasdaq Composite Index and the Nasdaq Biotechnology Index on May 9, 2019 and the reinvestment of dividends into shares of common stock.
+Added: The comparisons in the table are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock.
+Added: This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
+Added: Company/Index
+Added: Cortexyme, Inc
+Added: Nasdaq Composite Index
+Added: Nasdaq Biotechnology Index
Dividend Policy
4 unchanged sentences
Sales of Unregistered Securities
−Removed: From January 1, 2019 through May 9, 2019 (the date of the filing of our registration statement on Form S-8), we issued and sold to our employees, consultants and other service providers an aggregate of unregistered 158,236 shares of common stock upon the exercise of stock options under our 2014 Plan.
−Removed: The securities issued in these transactions were exempt from the registration requirements of the Securities Act in reliance upon Rule 701 promulgated under the Securities Act or Section 4(a)(2) of the Securities Act.
Use of Proceeds
1 unchanged sentence
333-230853) was declared effective by the SEC for our IPO.
−Removed: At the closing of our IPO on May 13, 2019 we sold 5,073,800 shares of common stock which included the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of $17.00 per share and received gross proceeds of $86.3 million, which resulted in net proceeds to us of approximately $77.8 million, after deducting underwriting discounts and commissions of approximately $6.0 million and offering related transaction costs of approximately $2.5 million.
−Removed: None of the expenses associated with the IPO were paid to directors, officers, persons owning ten percent or more of any class of equity securities or to their affiliates.
−Removed: Merrill Lynch, Pierce, Fenner & Smith Incorporated and Credit Suisse Securities (USA) LLC.
−Removed: acted as joint book-running managers for the offering.
+Added: At the closing of our IPO on May 13, 2019 we sold 5,073,800 shares of common stock which included the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of $17.00 per share and received gross proceeds of $86.3 million, which resulted in net proceeds to us of approximately $77.8 million, after deducting underwriting discounts and commissions and offering related transaction costs.
There has been no material change in the planned use of proceeds from our IPO from that described in the final prospectus filed by us with the SEC on May 9, 2019.
1 unchanged sentence
Item 6 Selected Financial Data
−Removed: Not required as a smaller reporting company.
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.